Enregistré dans:
Détails bibliographiques
Auteurs principaux: Esther Gómez‐Soto, Miriam Guedra‐Allais, Alice Le‐Gal, Daria Starybrat
Format: Artículo Open Access
Publié: Wiley 2026
Sujets:
Accès en ligne:https://onlinelibrary.wiley.com/doi/10.1111/vec.70100
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
_version_ 1867002614351134720
author Esther Gómez‐Soto
Miriam Guedra‐Allais
Alice Le‐Gal
Daria Starybrat
author_facet Esther Gómez‐Soto
Miriam Guedra‐Allais
Alice Le‐Gal
Daria Starybrat
Esther Gómez‐Soto
Miriam Guedra‐Allais
Alice Le‐Gal
Daria Starybrat
collection Wiley Open Access
contents Multicenter Retrospective Study of Xenotransfusion of Canine Plasma Products to Cats: 14 Cases (2022–2024) Esther Gómez‐Soto Miriam Guedra‐Allais Alice Le‐Gal Daria Starybrat Journal of Veterinary Emergency and Critical Care ABSTRACT Objective To determine the indications, transfusion protocols, transfusion reactions, and outcomes of cats that received canine plasma products. Design Retrospective, descriptive study from 2022 to 2024. Setting Multicenter study from one university teaching hospital and two private referral hospitals. Animals Fourteen client‐owned cats that were transfused with canine plasma products and had transfusion records available. Interventions None. Measurements and Main Results Fourteen cats received 16 canine plasma transfusions. The reasons for canine plasma xenotransfusion were confirmed coagulopathy (7/14), suspected coagulopathy (1/14), oncotic support (5/14), and severe hypovolemia (1/14). Six cats were found to be coagulopathic based on pretransfusion activated partial thromboplastin time (aPTT) and prothrombin time (PT). Three of these cats achieved normalization of both PT and aPTT after plasma xenotransfusion; one cat achieved normalization of PT only, and one cat had normalization of aPTT and mild prolongation of PT posttransfusion (<1.5‐fold elevation of the upper reference interval). The median volume of canine plasma products administered was 11.35 mL/kg (range: 5.25–31.9), and the median time in which the plasma xenotransfusion was completed was 3.9 h (range: 0.15–24). Only six cats received canine plasma products exclusively. Of these six cats, two (33.3%) were suspected to experience signs of acute transfusion reactions, categorized as acute respiratory distress. Five cats (35.7%) survived to discharge, six (42.9%) were euthanized, and three (21.4%) experienced cardiopulmonary arrest. Conclusions Canine plasma xenotransfusions to cats can be considered a life‐saving option in the absence of feline plasma products for the treatment of coagulopathies and colloidal support. However, the safety profile of canine plasma transfusions in cats remains to be determined. 10.1111/vec.70100 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1111/vec.70100
format Artículo Open Access
id wiley_oa_10_1111_vec_70100
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle Multicenter Retrospective Study of Xenotransfusion of Canine Plasma Products to Cats: 14 Cases (2022–2024)
Esther Gómez‐Soto
Miriam Guedra‐Allais
Alice Le‐Gal
Daria Starybrat
Journal of Veterinary Emergency and Critical Care
Multicenter Retrospective Study of Xenotransfusion of Canine Plasma Products to Cats: 14 Cases (2022–2024) Esther Gómez‐Soto Miriam Guedra‐Allais Alice Le‐Gal Daria Starybrat Journal of Veterinary Emergency and Critical Care ABSTRACT Objective To determine the indications, transfusion protocols, transfusion reactions, and outcomes of cats that received canine plasma products. Design Retrospective, descriptive study from 2022 to 2024. Setting Multicenter study from one university teaching hospital and two private referral hospitals. Animals Fourteen client‐owned cats that were transfused with canine plasma products and had transfusion records available. Interventions None. Measurements and Main Results Fourteen cats received 16 canine plasma transfusions. The reasons for canine plasma xenotransfusion were confirmed coagulopathy (7/14), suspected coagulopathy (1/14), oncotic support (5/14), and severe hypovolemia (1/14). Six cats were found to be coagulopathic based on pretransfusion activated partial thromboplastin time (aPTT) and prothrombin time (PT). Three of these cats achieved normalization of both PT and aPTT after plasma xenotransfusion; one cat achieved normalization of PT only, and one cat had normalization of aPTT and mild prolongation of PT posttransfusion (<1.5‐fold elevation of the upper reference interval). The median volume of canine plasma products administered was 11.35 mL/kg (range: 5.25–31.9), and the median time in which the plasma xenotransfusion was completed was 3.9 h (range: 0.15–24). Only six cats received canine plasma products exclusively. Of these six cats, two (33.3%) were suspected to experience signs of acute transfusion reactions, categorized as acute respiratory distress. Five cats (35.7%) survived to discharge, six (42.9%) were euthanized, and three (21.4%) experienced cardiopulmonary arrest. Conclusions Canine plasma xenotransfusions to cats can be considered a life‐saving option in the absence of feline plasma products for the treatment of coagulopathies and colloidal support. However, the safety profile of canine plasma transfusions in cats remains to be determined. 10.1111/vec.70100 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Multicenter Retrospective Study of Xenotransfusion of Canine Plasma Products to Cats: 14 Cases (2022–2024)
topic Journal of Veterinary Emergency and Critical Care
url https://onlinelibrary.wiley.com/doi/10.1111/vec.70100